Clinical Trial Update: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 [Phase 3]

View source ↗

Summary

Phase 3 trial ABTECT-2 evaluating ABX464 for ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ABX464 (ABX464)

Snippet

Sponsor: Abivax S.A. | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED